American Association for Cancer Research
crc-23-0075_fig2.png (232.44 kB)

FIGURE 2 from Prediagnostic CT or MRI Utilization and Outcomes in Hepatocellular Carcinoma: SEER-Medicare Database Analysis

Download (232.44 kB)
posted on 2023-05-16, 14:20 authored by Mohammad A. Karim, Amit G. Singal, Hye Chung Kum, Yi-Te Lee, Sulki Park, Nicole E. Rich, Mazen Noureddin, Ju Dong Yang

OS estimates by Imaging group. Comparison of OS between patients with HCC receiving different types of imaging without adjustment for lead-time bias (A) and after adjustment for lead-time bias with mean sojourn time of 6 months (B). Median OS was 20.5 months (95% CI: 19–22 months), 15 months (95% CI: 13–17 months), and 10 months (95% CI: 9–11 months) for CT/MRI, US, and no imaging, respectively without adjustment for lead-time bias. Median OS was 16.7 months (95% CI: 15.8–18.6 months) and 12 months (95% CI: 10.7–14.1 months) for CT/MRI and US, respectively, with adjustment for lead-time bias. Lead-time adjustment would not affect median OS of no imaging group. CT, computed tomography; HCC, hepatocellular carcinoma; MRI, magnetic resonance imaging; US, ultrasound.


Cancer Prevention and Research Institute of Texas (CPRIT)

HHS | National Institutes of Health (NIH)

Population Informatics Lab at Texas A&M University

Texas Virtual Data Library at Texas A&M University

American College of Gastroenterology (ACG)

DOD | USA | MEDCOM | CDMRP | DOD Peer Reviewed Cancer Research Program (PRCRP)



Our population-based study using SEER-Medicare database demonstrated that proportion of time covered by abdominal imaging was associated with improved survival in patients with HCC, with potential greater benefit using CT/MRI. The results suggest that CT/MRI surveillance may have potential survival benefit compared with ultrasound surveillance in high-risk patients for HCC. A larger prospective study should be conducted for external validation.